These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 19448418)
21. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression]. Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494 [TBL] [Abstract][Full Text] [Related]
22. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486 [TBL] [Abstract][Full Text] [Related]
23. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma]. Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192 [TBL] [Abstract][Full Text] [Related]
24. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology. Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480 [TBL] [Abstract][Full Text] [Related]
25. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong. Lo S; Ho WK; Wei WI Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma. Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579 [TBL] [Abstract][Full Text] [Related]
27. [Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma]. Cai YL; Li J; Lu AY; Zhong WM; Zheng YM; Gao JQ; Zeng H; Chen WS; Liang W; Tang MZ Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):119-22. PubMed ID: 24044217 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473 [TBL] [Abstract][Full Text] [Related]
29. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545 [TBL] [Abstract][Full Text] [Related]
30. [Expression of P53 and PCNA in nasopharyngeal carcinoma and their relation with clinical stage, VCA/IgA, EA/IgA, radiation sensibility, and pognosis]. Mo HY; Zhang CQ; Feng KT; Zhang F; Hong MH; Sun ZY Ai Zheng; 2004 Nov; 23(11 Suppl):1551-4. PubMed ID: 15566678 [TBL] [Abstract][Full Text] [Related]
31. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043 [TBL] [Abstract][Full Text] [Related]
32. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA]. Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122 [TBL] [Abstract][Full Text] [Related]
33. Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma. Zhang C; Zong Y; Huang B; Sun Y; Ye Y; Feng K; Li J; Zhang F Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):356-9. PubMed ID: 12408763 [TBL] [Abstract][Full Text] [Related]
34. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients. Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351 [TBL] [Abstract][Full Text] [Related]
35. [Clinical analysis of 1,142 hospitalized cantonese patients with nasopharyngeal carcinoma]. Cao SM; Guo X; Li NW; Xiang YQ; Hong MH; Min HQ Ai Zheng; 2006 Feb; 25(2):204-8. PubMed ID: 16480587 [TBL] [Abstract][Full Text] [Related]
36. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
37. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618 [TBL] [Abstract][Full Text] [Related]
38. Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. Cao SM; Liu Z; Jia WH; Huang QH; Liu Q; Guo X; Huang TB; Ye W; Hong MH PLoS One; 2011 Apr; 6(4):e19100. PubMed ID: 21544243 [TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus serological markers for nasopharyngeal carcinoma in Thailand. Puthavathana P; Sutthent R; Vitavasiri A; Wasi C; Chantarakul N; Thongcharoen P Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):326-31. PubMed ID: 1818381 [TBL] [Abstract][Full Text] [Related]
40. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies. Chen Y; Yao K; Sun H; Qing J; Peng GY Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]